2021
856. Barriers to PrEP Implementation among Patient-Facing Staff in Three Urban Clinics
Shenoi S, Sideleau R, McKay S, Aoun-Barakat L. 856. Barriers to PrEP Implementation among Patient-Facing Staff in Three Urban Clinics. Open Forum Infectious Diseases 2021, 8: 519-519. DOI: 10.1093/ofid/ofab466.1051.Peer-Reviewed Original ResearchPrEP implementationPrEP uptakeSafety of PrEPQualified health centersLack of insuranceMultidisciplinary team membersDuration of employmentGuidelines/protocolsPrEP efficacyPrEP servicesMedian durationPrEP useUrban clinicPrEP rolloutHealth centersSafety dataProvider trainingPatient outreachSide effectsSystemic barriersMultidisciplinary staffSexual riskPatientsBehavioral interventionsPrescribers
2018
Dolutegravir/rilpivirine for the treatment of HIV-1 infection
Dowers E, Zamora F, Barakat LA, Ogbuagu O. Dolutegravir/rilpivirine for the treatment of HIV-1 infection. HIV/AIDS - Research And Palliative Care 2018, 10: 215-224. PMID: 30464642, PMCID: PMC6220428, DOI: 10.2147/hiv.s157855.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsHIV-1 infectionDolutegravir/rilpivirineAntiretroviral therapyImportant drug-drug interactionsClinical trial efficacyDrug-drug interactionsImproved safety profileLong-term toxicityDrug package insertsRegimen simplificationMaintenance therapyCombination regimensMedication adherenceSafety profileSafety dataTrial efficacyConference abstractsPackage insertsDrug AdministrationUS FoodPharmacokinetic propertiesGoogle ScholarInfectionLimited dataRilpivirine